Understanding the TYK2/STAT Signaling Pathway in PsA: Clinical Implications and Beyond

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers (RhAPP), host Amanda Mixon, PA-C, dives into the evolving role of TYK2 inhibition in the treatment of psoriatic arthritis (PsA). Joined by special guest and PsA expert Eileen Lydon, NP, the episode unpacks the science behind the TYK2/STAT signaling pathway, how it differs from traditional JAK inhibition, and what this means for patient care. Together, Amanda and Eileen explore key cytokines like IL-12, IL-23, and type I interferons, and how selective TYK2 inhibitors such as deucravacitinib offer targeted modulation with a potentially improved safety profile.

Listeners will gain valuable insight into recent clinical trial data, including promising Phase 2 and Phase 3 results in PsA, as well as long-term safety outcomes from psoriasis studies with over five years of data. Eileen shares her practical clinical perspective on where TYK2 inhibitors may fit within the current PsA treatment landscape—especially for patients seeking oral options, those with comorbidities, or those who struggle with adherence to injectable or monitored therapies. The episode also highlights the findings from a recent expert consensus panel published in the Journal of Drugs in Dermatology, supporting the favorable safety profile of deucravacitinib without the need for extensive lab monitoring.

Whether you're a rheumatology provider, fellow, or someone exploring new therapeutic strategies, this episode delivers actionable insights into precision medicine and the future of TYK2-targeted care.

Explore more expert content at RhAPP.org or download the RhAPP ACE app.